Theratechnologies Inc. (THTX) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Theratechnologies Inc.

THTX

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

106M

Drug Manufacturers - Specialty & Generic

Next Earning date - 09 Jul 2025

106M

Drug Manufacturers - Specialty & Generic

Next Earning date - 09 Jul 2025

2.30USD

-0.06 ( -2.54%)

Market Closed (as of Jul 01, 20:00 EDT)

Relative Strenght

Volume Buzz

-98%

Earning Acce

Dist 52w H.

27%

Overview Chart

Quote Panel

Updated July 2, 2025

1W -1.71 % 1M -11.88 % 3M 63.12 % 1Y 70.37 %

Key Metrics

Market Cap
105.75M
Shares Outstanding
45.98M
Share in Float
36.33M
Dividende
0

Earning Date
09 Jul 2025
Price Target
2.3
Average Volume
2.17M
Beta
0.894

Range
1.12-3.13
Industry
Drug Manufacturers - Specialty & Generic
Website
https://www.theratech.com
Sector
Healthcare

Quote Panel

Updated July 2, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

1.25x

P/S Ratio

-4.81x

P/B Ratio

-2.1

Debt/Equity

-4.2%

Net Margin

$-0.1

EPS

How THTX compares to sector?

P/E Ratio

Fundamentals

Relative Strength

THTX

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

THTX

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$95M

400%

2026-Revenue

$0.29

11983%

2026-EPS

$15M

-846%

2026-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Cantor Fitzgerald

initialise

Previous: Not converted

2022-11-17

Now: Overweight

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q2.23

N/A

-0.40
vs -0.96

Q3.23

N/A

-0.03
vs -0.32

Q4.23

N/A

-0.08
vs -0.36

Q1.24

N/A

-0.10
vs -0.44

Q2.24

+105%

0.02
vs -0.40

Q3.24

+300%

0.06
vs -0.03

Q4.24

N/A

-0.09
vs -0.08

Q1.25

+102%

0
vs -0.10

Q2.25

N/A

-0.01
vs 0.02

Q3.25

-25%

0.04
vs 0.06

Sales Growth

YoY

Current

Estimates

Q2.23

-9%

17.5M vs 19.3M

Q3.23

+0%

20.9M vs 20.8M

Q4.23

+9%

23.5M vs 21.4M

Q1.24

-19%

16.1M vs 19.9M

Q2.24

+25%

22M vs 17.5M

Q3.24

+8%

22.6M vs 20.9M

Q4.24

+7%

25M vs 23.5M

Q1.25

+18%

19M vs 16.1M

Q2.25

-21%

17.5M vs 22M

Q3.25

-4%

21.6M vs 22.6M

Return on Equity

QoQ

Q2.23

+24%

0.24
vs 0.32

Q3.23

+2%

0.02
vs 0.24

Q4.23

+13%

0.13
vs 0.02

Q1.24

+18%

0.18
vs 0.13

Q2.24

-4%

-0.04
vs 0.18

Q3.24

-16%

-0.16
vs -0.04

Q4.24

+31%

0.31
vs -0.16

Q1.25

-0.00
vs 0.31

Institutionnal Ownership

QoQ

Q2.23

42
vs 42

Q3.23

30
vs 42

-29%

Q4.23

32
vs 30

Q1.24

35
vs 32

Q2.24

34
vs 35

-3%

Q3.24

39
vs 34

15%

Q4.24

42
vs 39

Q1.25

38
vs 42

-10%

Earnings Growth

Latest News

globenewswire.com

7 hours ago

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

businesswire.com

8 hours ago

Soleus Capital Issues Letter to The Board of Theratechnologies

seekingalpha.com

12 hours ago

Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer

globenewswire.com

14 hours ago

Theratechnologies Reports on its Annual Meeting of Shareholders

globenewswire.com

17 hours ago

Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

globenewswire.com

18 hours ago

Theratechnologies Provides Update on Sale Process

Company Description

2.30USD

N/A

1.25x

-4.81x

-2.1

-4.2%

$-0.1

$95M

$0.29

$15M

Earnings Growth

Latest News

$95M

$0.29

$15M

Company Description

2.30USD

N/A

1.25x

-4.81x

-2.1

-4.2%

$-0.1